CHM 12.5% 1.8¢ chimeric therapeutics limited

CLTX-CAR T is a game changer, page-14

  1. 691 Posts.
    lightbulb Created with Sketch. 116
    It is well-established that PD-L1 expression can be induced by IFNγ signaling leading to tumor adaptive resistance to immunotherapy.

    Although other immunosuppressive mechanisms may be involved, these observations suggest that immunostimulatory cytokines produced by activated CAR T cells can induce GBM adaptive resistance pathways, such as PD-L1 induction, and hinder tumor eradication by CAR T cells.

    Our results lead to the potential of correlating tumor IFNγ receptor expression with CLTX-CAR T cell therapeutic effect, as well as the possibility of combining CLTX-CAR T cells with checkpoint inhibitors for more effective GBM clearances.


    Guessing that they are going with CLTX effect only - and the outcome will be heavily determined by how much PD-L1 expression there is. Low in vivo numbers here, and still a clear effect in the worst case scenario (high PD-L1).

    A/B is low (PBT106)
    C/D is high (PBT 003-4)

    https://hotcopper.com.au/data/attachments/2963/2963431-669a80a0369df61326b02c9fed53026f.jpg





 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
(20min delay)
Last
1.8¢
Change
0.002(12.5%)
Mkt cap ! $15.96M
Open High Low Value Volume
1.7¢ 2.0¢ 1.7¢ $28.92K 1.577M

Buyers (Bids)

No. Vol. Price($)
1 95523 1.8¢
 

Sellers (Offers)

Price($) Vol. No.
1.9¢ 2523 1
View Market Depth
Last trade - 16.10pm 09/08/2024 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.